Scientists in America have developed a personalized vaccine that reduces the risk of cancer recurrence and death in patients with melanoma, but studies are still ongoing. (translated)
Vėžio gydyme – žinia, kurios laukė daugelis
Pharmaceutical companies "Moderna" and "Merck" have successfully completed large-scale studies on a personalized mRNA vaccine for melanoma, which may effectively prevent the recurrence of the disease and the spread of metastases. (translated)
Revoliucija onkologijoje: „Moderna“ melanomos vakcina sėkmingai praėjo didelio masto tyrimus
E
The enthusiasm for Moderna and MSD's personalized mRNA vaccine against melanoma has led to a notable increase in the company's market capitalization, despite the fact that the results have not yet been fully presented and experts warn about the limitations of its effectiveness in other types of cancer. (translated)
El entusiasmo por la vacuna contra el cáncer de Moderna crece más rápido que los datos
The personalized mRNA vaccine, developed in collaboration between Moderna and Merck, has achieved a significant breakthrough in the treatment of melanoma, as it helps the immune system recognize cancer cells after surgery and reduces the risk of disease recurrence, as demonstrated by a successfully completed phase three clinical trial. (translated)
Cepivo proti raku po meri bolnika doseglo pomemben preboj
A vaccine against melanoma? What is really behind the announcement from MSD and Moderna (translated)
Pharmaceutical companies MSD and Moderna have announced positive results from a clinical trial of a personalized therapeutic vaccine aimed at reducing the risk of relapse in melanoma patients, although they have not yet provided specific details about the efficacy of the therapy combined with immunotherapy, which has driven up their stock value. (translated)
¿Una vacuna contra el melanoma? Qué hay realmente detrás del anuncio de MSD y Moderna
The article discusses the promising results of a study on vaccines for the treatment of melanoma, one of the most aggressive types of skin cancer, and features the participation of researchers Bruno Sarmento and Paula Videira, raising the question of whether this could be the path to a cure for the disease. (translated)
A cura para o cancro está nas vacinas?
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw #mRNAvaccine #CancerResearch #Immunotherapy #Nospecificcountrycodesarementionedinthetweet.
The friend, colleague, and university mate at Gemelli @curijoey reminds us that the data on the melanoma vaccine will be presented at the European Society for Medical Oncology (ESMO) conference, of which he is the elected president. (translated)
Moderna and Merck have announced an important discovery in cancer vaccine research, demonstrating the effectiveness of an experimental mRNA vaccine called Intismeran in combination with the immunotherapy Keytruda for the treatment of melanoma, the most aggressive type of skin cancer. (translated)
C’è un importante risultato nella ricerca sui vaccini contro il cancro
VACCINE AGAINST CANCER, MADE FROM TUMOR In a regular vaccine, we all receive the same active ingredient. In the new melanoma treatment, it is just the opposite: a special vaccine is made for each patient from data about their tumor. The process begins after surgery. From the removed tumor (translated)
The experimental vaccine against melanoma, announced by Moderna and Merck after passing a clinical trial, generates excitement in the medical community for its potential as a historic advancement, although caution is also expressed due to the lack of detailed data on its effectiveness. (translated)
La vacuna experimental del melanoma, entre la expectación por un posible avance histórico y la cautela por falta de datos
La scienza avanza verso il vaccino a mRNA contro il #melanoma, e ci sono speranze per pancreas, polmone e alcuni tumori al seno. I trogloditi dei novax continueranno nel loro oscurantismo ma solo il progresso ci salva. #fiducianellascienza #vaccino #scienza #progresso
Direi che la notizia del giorno è il risultato positivo per il vaccino anti melanoma. Meno recidive e meno metastasi nei pazienti operati. Non è un vaccino che impedisce di ammalarsi: viene creato per ogni singolo paziente partendo dalle mutazioni del suo tumore. W la scienza! #Vaccino #Melanoma #Scienza
Moderna's new mRNA-based vaccine has achieved significant success in preventing the recurrence of melanoma, which could serve as a milestone in the treatment of skin cancer, and the pharmaceutical company's stock price has risen by more than 145% following the announcement. (translated)
Áttörés a bőrrák kezelésében: megakadályozza a melanóma kiújulását a Moderna készítménye
Il successo del vaccino a mRNA contro il melanoma, emerso da uno studio randomizzato di Fase 3 definitivo, si aggiunge ai segnali di efficacia dei vaccini personalizzati a mRNA basati su neoantigeni contro il tumore del pancreas, il tumore al seno triplo-negativo e il tumore del polmone. Vaccino per molti, ma non per tutti… Questi dati, infatti, non faranno cambiare idea a quei trogloditi dei #novax che continueranno a chiamarli sieri genici sperimentali. Peggio per loro! https://t.co/zzPEtEdgkV #Vaccino #mRNA #Cancro
The mRNA vaccine developed by Moderna and Merck against the recurrence of melanoma has shown promising results in a phase 3 clinical trial, leading to a significant increase in Moderna's stock and suggesting a new personalized approach in the fight against this form of cancer. (translated)
“Risultati promettenti” per il vaccino a mRna contro la recidiva del melanoma. Le azioni di Moderna volano in Borsa
An experimental vaccine against melanoma developed by Merck and Moderna showed promising results in its first phase 3 clinical study, leading to a 130% increase in Moderna's shares and a 10.8% increase for Merck. (translated)
Il vaccino contro il melanoma mostra risultati promettenti, Moderna vola in Borsa a +130%
Moderna and Merck announced positive results from a phase 3 clinical trial of the intismeran vaccine, a personalized mRNA-based therapy against melanoma, which demonstrated a reduced risk of recurrence and metastasis in melanoma patients following complete surgical tumor removal when combined with the immunotherapy pembrolizumab. (translated)
La vacuna personalizada contra el melanoma da un paso histórico tras superar su gran ensayo clínico
